ReviewArchives of biochemistry and biophysics2007
NOX in liver fibrosis.
Review in Archives of biochemistry and biophysics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01598064 (Clinical Trial of Probiotics in Preventing Complication Related to Portal Hypertension in Cirrhotic Patients), which is not on this map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Trial of Probiotics in Preventing Complication Related to Portal Hypertension in Cirrhotic Patients
Who cites it
69 citing papers in PubMed, 159 citations in OpenAlex.
- Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C.American journal of physiology. Gastrointestinal and liver physiology · 2009Trial
- Pathogenesis, Non-Invasive Assessments and Treatment of Hepatic Fibrosis in Autoimmune Liver Diseases.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- Nicotinamide Adenine Dinucleotide Phosphate Oxidases and Metabolic Dysfunction-Associated Steatotic Liver Disease.Antioxidants (Basel, Switzerland) · 2025Review
- Traditional Chinese medicine inspired dual-drugs loaded inhalable nano-therapeutics alleviated idiopathic pulmonary fibrosis by targeting early inflammation and late fibrosis.Journal of nanobiotechnology · 2024Article
- Involvement of NOX2-derived ROS in human hepatoma HepG2 cell death induced by Entamoeba histolytica.Parasites, hosts and diseases · 2023Article
- Cellular heterogeneity and plasticity during NAFLD progression.Frontiers in molecular biosciences · 2023Review
- NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook.Antioxidants (Basel, Switzerland) · 2022Review
- A New Murine Liver Fibrosis Model Induced by Polyhexamethylene Guanidine-Phosphate.Biomolecules & therapeutics · 2022Article
- The TGF-β/NADPH Oxidases Axis in the Regulation of Liver Cell Biology in Health and Disease.Cells · 2021Review
- The Overactivation of NADPH Oxidase duringAntioxidants (Basel, Switzerland) · 2021Article
- NOX1 inhibition attenuates the development of a pro-tumorigenic environment in experimental hepatocellular carcinoma.Journal of experimental & clinical cancer research : CR · 2021Article
- Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy.Frontiers in cell and developmental biology · 2021Review
- Cytoglobin-expressing cells in the splenic cords contribute to splenic fibrosis in cirrhotic patients.Histology and histopathology · 2020Article
- Chymase as a Possible Therapeutic Target for Amelioration of Non-Alcoholic Steatohepatitis.International journal of molecular sciences · 2020Review
- Mechanisms of liver fibrosis and its role in liver cancer.Experimental biology and medicine (Maywood, N.J.) · 2020Review
- Chronic restraint stress induces esophageal fibrosis with enhanced oxidative stress in a murine model.Experimental and therapeutic medicine · 2019Article
- Apocynin Dietary Supplementation Delays Mouse Ovarian Ageing.Oxidative medicine and cellular longevity · 2019Article
- Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis.Frontiers in pharmacology · 2018Review
- Hepatic Fibrosis in Dogs.Journal of veterinary internal medicine · 2018Review
- NADPH Oxidase Signaling Pathway Mediates Mesenchymal Stem Cell-Induced Inhibition of Hepatic Stellate Cell Activation.Stem cells international · 2018Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
NADPH oxidase is a multi-protein complex producing reactive oxygen species (ROS) both in phagocytic cells, being essential in host defense, and in non-phagocytic cells, regulating intracellular signalling. In the liver, NADPH oxidase plays a central role in fibrogenesis. A functionally active form of the NADPH oxidase is expressed not only in Kupffer cells (phagocytic cell type) but also in hepatic stellate cells (HSCs) (non-phagocytic cell type), suggesting a role of the non-phagocytic NADPH oxidase in HSC activation. Consistent with this concept, profibrogenic agonists such as Angiotensin II (Ang II) and platelet derived growth factor (PDGF), or apoptotic bodies exert their activity through NADPH oxidase-activation in HSCs. Both pharmacological inhibition with DPI and genetic studies using p47(phox) knockout mice provided evidence for a central role of NADPH oxidase in the regulation of HSC-activity and liver fibrosis. In addition to the p47(phox) component, only Rac1 has been identified as a functional active component of the NADPH oxidase complex in HSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.